Juniper Research updates its mHealth study from the spring [TA 22 April] on its blog with a few thoughts. While cardiac monitoring accounts for most of the present activity, the ‘secondary’ diseases for monitoring, including diabetes, COPD and asthma, could eventually be a much larger market. Interesting fact: most companies in chronic disease management are venture-backed at $10 million or less. Cost savings? Yes, maybe, and these companies have to convince the payor market of it to break out of this ‘shell’. AnalystXpress blog.